| Literature DB >> 34716617 |
Yorka Muñoz1, Francisco Cuevas-Pacheco2,3, Gaël Quesseveur1, Keith K Murai1,4.
Abstract
Astrocytes are abundant cells of the central nervous system (CNS) and are involved in processes including synapse formation/function, ion homeostasis, neurotransmitter uptake, and neurovascular coupling. Recent evidence indicates that astrocytes show diverse molecular, structural, and physiological properties within the CNS. This heterogeneity is reflected in differences in astrocyte structure, gene expression, functional properties, and responsiveness to injury/pathological conditions. Deeper investigation of astrocytic heterogeneity is needed to understand how astrocytes are configured to enable diverse roles in the CNS. While much has been learned about astrocytic heterogeneity in rodents, much less is known about astrocytic heterogeneity in the primate brain where astrocytes have greater size and complexity. The common marmoset (Callithrix jacchus) is a promising non-human primate model because of similarities between marmosets and humans with respect to genetics, brain anatomy, and cognition/behavior. Here, we investigated the molecular and structural heterogeneity of marmoset astrocytes using an array of astrocytic markers, multi-label confocal microscopy, and quantitative analysis. We used male and female marmosets and found that marmoset astrocytes show differences in expression of astrocytic markers in cortex, hippocampus, and cerebellum. These differences were accompanied by intra-regional variation in expression of markers for glutamate/GABA transporters, and potassium and water channels. Differences in astrocyte structure were also found, along with complex interactions with blood vessels, microglia, and neurons. This study contributes to our knowledge of the cellular and molecular features of marmoset astrocytes and is useful for understanding the complex properties of astrocytes in the primate CNS.Entities:
Keywords: RRID:AB_10641162; RRID:AB_10673392; RRID:AB_11122614; RRID:AB_141607; RRID:AB_141844; RRID:AB_142581; RRID:AB_162542; RRID:AB_2059853; RRID:AB_2110656; RRID:AB_2194160; RRID:AB_2340472; RRID:AB_2340476; RRID:AB_2340961; RRID:AB_2340962; RRID:AB_2534013; RRID:AB_2534017; RRID:AB_2534102; RRID:AB_2535792; RRID:AB_2536183; RRID:AB_2620004; RRID:AB_2763902; RRID:AB_297885; RRID:AB_304334; RRID:AB_397474; RRID:AB_476894; RRID:AB_477499; RRID:AB_839504; RRID:AB_90949; astrocytes; cerebellum; confocal imaging; cortex; heterogeneity; hippocampus; marmoset; statistical analysis
Mesh:
Year: 2021 PMID: 34716617 PMCID: PMC9541330 DOI: 10.1002/jnr.24967
Source DB: PubMed Journal: J Neurosci Res ISSN: 0360-4012 Impact factor: 4.433
List of primary antibodies used
| Name | Immunogen | Details | Concentration/working dilution |
|---|---|---|---|
| Anti‐GFAP antibody produced in guinea pig | Recombinant protein corresponding to AA 1 to 432 from human GFAP | Synaptic systems, # 173004, polyclonal guinea pig antiserum, RRID:AB_10641162 | Not provided/1:500 |
| Anti‐S100β antibody produced in mouse | Bovine brain S‐100b | Sigma‐Aldrich, # S2532, monoclonal antibody, RRID:AB_477499 | Not provided/1:500 |
| Anti‐GS antibody produced in mouse | Glutamine synthetase purified from sheep brain | Millipore, # MAB302, monoclonal antibody, RRID:AB_2110656 | 2 μg/ml/1:500 |
| Anti‐Sox9 antibody produced in goat |
| R&D system, # AF3075, polyclonal antibody, RRID:AB_2194160 | 4 μg/ml/1:250 |
| Anti‐Calbindin (D28K) antibody produced in mouse | Bovine kidney Calbindin‐D | Sigma‐Aldrich, # C9848, monoclonal antibody, RRID:AB_476894 | Not provided/1:250 |
| Anti‐EAAT2 antibody produced in guinea pig | Synthetic peptide from the carboxy‐terminus of rat GLT‐1 | Millipore, # AB1783, polyclonal antibody, RRID:AB_90949 | Not provided/1:500 |
| Anti‐EAAT1 | Synthetic peptide corresponding to Rat EAAT1 (C terminal, 20 residues) | Abcam, # Ab416, polyclonal antibody, RRID:AB_304334 | 2 μg/ml/1:500 |
| Anti‐Kir4.1 antibody produced in guinea pig | Peptide corresponding to AA 356‐375 of rat Kir4.1 | Alomone labs, # AGP‐012, polyclonal antibody, RRID:AB_2340962 | 1.6 μg/ml/1:500 |
| Anti‐GAT3 antibody produced in guinea pig | Synthetic peptide corresponding to AA 612 to 627 of mouse GAT3 | Synaptic systems, # 274304, polyclonal guinea pig antiserum, RRID:AB_2620004 | Not provided/1:500 |
| Anti‐AQP4 antibody produced in goat | Peptide mapping at the C‐terminus of human AQP4 | Santa Cruz Biotechnology, # SC‐9888, polyclonal antibody, RRID:AB_2059853 | 2 μg/ml/1:500 |
| KO validated | |||
| Anti‐AQP4 antibody produced in rabbit | Peptide corresponding to AA 300‐314 of rat AQP4 | Alomone lab, # AQP4‐014, polyclonal antibody, RRID:AB_11122614 | 1.6 μg/ml/1:500 |
| Anti‐GluA1 antibody produced in guinea pig | Peptide corresponding to AA 271‐285 of rat GluR1 | Alomone lab, # AGP‐009, Polyclonal antibody, RRID:AB_2340961 | 3.2 μg/ml/1:250 |
| Anti‐Cx43 antibody produced in mouse | Peptide corresponding to AA 252‐270 of Rat Connexin‐43 | BD transduction, # 610062, monoclonal antibody, RRID:AB_397474 | 0.5 μg/ml/1:500 |
| Anti‐Lam antibody produced in rabbit | Recombinant fusion protein corresponding to AA 862‐1111 of human LAMC2 | ABClonal, # A1869, polyclonal antibody, RRID:AB_2763902 | Not provided/1:50 |
| Anti‐Iba1 antibody produced in rabbit | Synthetic peptide, C‐terminal of Iba1 | WAKO, # 019‐19741, polyclonal antibody, RRID:AB_839504 | 1 μg/ml/1:500 |
| Anti‐MAP2 antibody produced in mouse | HM‐2 hybridoma produced from mice immunized with Rat MAP2 | Abcam, # Ab11267, monoclonal antibody, RRID:AB_297885 | 2 μg/ml/1:250 |
| Anti‐Kv2.1 antibody produced in mouse | Synthetic peptide AA 837‐853, C‐ terminus of rat Kv2.1 | NeuroMAB, # 75014, monoclonal antibody RRID:AB_10673392 | 3.3 μg/ml/1:300 |
An antibody tested but not used for the study; See Table 2 for further details.
Antibodies used and amino acid conservation between species
| Antibody used in the study | Immunizing antigen (peptide or protein) and species | Amino acid (aa) identity conservation with marmoset ortholog | Alignment |
|---|---|---|---|
|
| |||
|
| |||
| EAAT2 | Not specified used last 25aa | 100% (25 of 25aa) |
|
| Rat | |||
| EAAT1 (omitted from study) | aa 524‐543 | 80% (16 of 20aa) |
|
| Rat | |||
| Kir4.1 | aa 356‐375 | 100% (20 of 20aa) |
|
| Rat | |||
| GAT3 | aa 612‐627 | 88% (14 of 16aa) |
|
| Mouse | |||
| GluA1 | aa 271‐285 | 80% (12 of 15aa) |
|
| Rat | |||
| AQP4 (Human) | Not Specified Used Last 20aa | 95% (19 of 20aa) |
|
| Human | |||
| AQP4 (Rat) | aa 300‐314 | 93.3% (14 of 15aa) |
|
| Rat | |||
| S100ß | aa 1‐92 | 96.7% (89 of 92aa) |
|
| Bovine | |||
| SOX9 | aa 1‐151 | 100% (151 of 151aa) |
|
| Human | |||
| GFAP | aa 1‐432 | 98.1% (424 of 432aa) |
|
| Human | |||
| GS | aa 1‐373 | 96% (358 of 373aa) |
|
| Sheep |
Listing of secondary antibodies used
| Name | Details | Concentration/working solution |
|---|---|---|
| Alexa Fluor 488 donkey anti‐guinea pig IgG | Jackson ImmunoResearch, # 706‐545‐148, RRID:AB_2340472 | 1.5 μg/ml/1:500 |
| Alexa Fluor 647 donkey anti‐guinea pig IgG | Jackson ImmunoResearch, # 706‐605‐148, RRID:AB_2340476 | 1.5 μg/ml/1:500 |
| Alexa Fluor 488 donkey anti‐mouse IgG | Thermo Fischer, # A21202, RRID:AB_141607 | 4 μg/ml/1:500 |
| Alexa Fluor 568 donkey anti‐mouse IgG | Thermo Fischer, # A10037, RRID:AB_2534013 | 4 μg/ml/1:500 |
| Alexa Fluor 647 donkey anti‐mouse IgG | Thermo Fischer, # A31571, RRID:AB_162542 | 4 μg/ml/1:500 |
| Alexa Fluor 488 donkey anti‐rabbit IgG | Thermo Fischer, # A21206, RRID:AB_2535792 | 4 μg/ml/1:500 |
| Alexa Fluor 568 donkey anti‐rabbit IgG | Thermo Fischer, # A10042, RRID:AB_2534017 | 4 μg/ml/1:500 |
| Alexa Fluor 647 donkey anti‐rabbit IgG | Thermo Fischer, # A31573, RRID:AB_2536183 | 4 μg/ml/1:500 |
| Alexa Fluor 488 donkey anti‐goat IgG | Thermo Fischer, # A11055, RRID:AB_2534102 | 4 μg/ml/1:500 |
| Alexa Fluor 568 donkey anti‐goat IgG | Thermo Fischer, # A11057, RRID:AB_142581 | 4 μg/ml/1:500 |
| Alexa Fluor 647 donkey anti‐goat IgG | Thermo Fischer, # A21447, RRID:AB_141844 | 4 μg/ml/1:500 |
FIGURE 4Heterogeneity of cortical astrocytes. Hierarchical clustering algorithm identified astrocytic clusters based on the KS distance displayed in the dendrogram (left panel on each row) for EAAT2 (A), GAT3 (B), and Kir4.1 (C). Distance measurements reveal significant separation of astrocytes into distinct clusters. Three different images from two different animals were analyzed for each marker. The spatial organization of astrocytes within clusters is represented a, b, and c. Each astrocyte was identified using GS expression and it was assigned to a region from the pial surface (Region 1, R1) to inner cortical layers (R2, R3, and R4). Scale bars: 50 μm. Each astrocyte was identified with a number, R1 and R3 numbers are indicated in white and R2 and R4 numbers indicated in yellow. Analysis of GS can be found in Figure S5. Every cluster was identified by a number and particular color and the percentage of cells in each cluster in regions 1–4 is shown in a′–c′
FIGURE 7Heterogeneity of hippocampal astrocytes. Hierarchical clustering algorithm identified different astrocytic clusters based on the KS distance displayed in the dendrogram (left panel on each row) for GFAP (A), AQP4 (B), and Kir4.1 (C). The spatial organization of astrocytes within clusters is represented at the right side of each image (a–c). Scale bars: 50 μm. Each astrocyte was detected using GS expression and it was assigned in S. radiatum, S. pyramidale, and S. oriens. Each astrocyte was identified with a number, S. radiatum and S. oriens in white and S. pyramidale in yellow. Analysis of GS, EAAT2, and GAT3 can be found in Figure S6. Every astrocyte within a cluster was identified and assigned a number with a particular color. The percentage of cells in each cluster in the S. oriens (Ori), S. pyramidale (Pyr), and S. radiatum (Rad) is shown in a′–c′
FIGURE 1Expression of astrocytic markers GS, Sox9, and S100β in the marmoset cerebral cortex. Labeling of coronal sections of marmoset temporal cortex with antibodies against GS (A), Sox9 (B), and S100β (C). Each immunolabeling is contrasted with DAPI staining in the second panel (blue staining). Right panels with lowercase letters (a′–c′) provide a representative view of a single cell labeling. Orange arrowheads show S100β labeling in an astrocytic endfoot in c′. Roman numerals at the left side of panels indicate approximate location of cortical layers. Scale bars: 50 μm in A–C and 20 μm in a′–c′. bv, blood vessel
FIGURE 2GFAP labels marmoset cortical astrocytic populations including complex interlaminar astrocytes. (A–E) Sparsely labeled GFAP‐positive astrocytes across cortical layers. The approximate location of cortical layers indicated by Roman numerals I to IV (yellow). Orange arrowheads show interlaminar processes and green arrowheads define protoplasmic astrocytes (A). Detailed images of an interlaminar astrocyte (B), protoplasmic astrocyte (C), astrocytic endfeet (D), and white matter astrocytes (E). DAPI (blue) is used as a nuclear marker and AQP4 (blue) as an endfoot marker. Scale bar: 50 μm (A), 20 μm (B, C, and E), and 5 μm (D). Subtypes of interlaminar astrocytes (ILA). Marmoset pial ILAs (F–J) and subpial ILAs (K–O) labeled by S100β (F, K), GS (G, L), Sox9 (H, M) and specific astrocytic markers such as Kir4.1 (I, N) and AQP4 (J, O). Yellow arrowheads show astrocytic soma and processes in F–O. Orange arrowheads describe a punctate AQP4 staining. Scale bars: 20 μm (F–O)
FIGURE 3Expression of glutamate and GABA transporters, and the potassium channel Kir4.1 in the marmoset cerebral cortex. Double immunostaining of excitatory amino acid transport 2 (EAAT2) and GS (A), GABA transporter 3 (GAT3) and GS (B) and inward rectifier‐type potassium channel Kir4.1 and GS (C) in coronal sections from marmoset temporal cortex. GS was used as a counter‐label due to its more homogenous distribution in cortical layers. a′–c′ show higher magnifications of white rectangle areas of merged images. Right panels show a heat map of each specific marker showing its expression density through cortical layers. Purple‐to‐blue color indicates lower intensity signal, while the red‐to‐yellow color means higher intensity signal. Scale bars: 50 μm in A–C and 20 μm in a′–c′. bv, blood vessel
FIGURE 5Expression of astrocytic markers in the marmoset hippocampus. Labeling of coronal sections of marmoset hippocampus with antibodies against GS (A), Sox9 (B), S100β (C), and GFAP (D). Scale bars: 50 μm. Right insets show a higher magnification of different areas of hippocampus: Stratum radiatum (S. rad), Stratum pyramidale (S. pyr), and Stratum oriens, scale bars: 20 μm. White rectangle areas show higher magnification images, scale bars: 20 μm. Each label is contrasted with DAPI nuclear staining (blue). Double immunostaining of GS and Sox9 (E), GS and GFAP (F), and S100β and GFAP (G) shows heterogeneity. Scale bars: 20 μm. Schematic diagram of the marmoset hippocampus (H) adapted from (Yuasa et al., 2010). CA1, field of CA1 of hippocampus; CA3, field of CA3 of hippocampus; Cd, caudate nucleus; DG, dentate gyrus; Er, entorhinal cortex; ITG, inferotemporal gyrus; LV, lateral ventricle; S, subiculum; TE, temporal cortex. Images detailed from astrocytic processes of astrocytes located at: the border of S. pyramidale (I)—apical processes (a), basal processes (b), S. radiatum (J), and hilus in dentate gyrus (K). Scale bars: 20 μm. (L–M) Degree of structural polarization of astrocytes in S. pyramidale and S. radiatum measured by percentage of total number of processes and quantification of length of astrocytic processes of astrocytes shown in I and J
FIGURE 6Expression of glutamate and GABA transporters, Kir4.1, and AQP4 in the marmoset hippocampus. Labeling of coronal sections of marmoset hippocampus with astrocytic markers associated with subpopulations of astrocytes. Double immunolabeling of EAAT2 and GS (A), GAT3 and GS (B), Kir4.1 and GS (C) and water channel Aquaporin 4 (AQP4) and GS (D). The third panel of each row shows a merged image and the fourth panel is a heat map showing the density of expression of each specific marker. A purple–blue color indicates lower intensity signal and red–yellow color means higher intensity signal. White arrows highlight areas of particularly high signal intensity. Scale bars: 50 μm
FIGURE 8Expression of astrocytic markers in the marmoset cerebellum. Labeling of coronal sections of the marmoset cerebellar cortex and white matter with antibodies against GFAP (A), S100β (B), GS (C), and Sox9 (D). General images show the molecular layer (ML), Purkinje cell layer (PCL), granule cell layer (GCL), and white matter (WM). Each immunolabel is contrasted with DAPI staining of nuclei (blue). Scale bars: 100 μm. Panels (a–d) show higher magnification images while panels (a′–d′) show labels with respect to DAPI signal (third panel). Purkinje cell bodies are indicated with white asterisks. Scale bars: 50 μm. Magnifications of individual Bergmann glia cells (BG), velate astrocytes (VA), and astrocytes located within the white matter (WM) are shown in the last panel and they are indicated with white arrows (BG) and arrowheads. Note the presence of many lateral processes of Bergmann glia (white arrows in GFAP, S100β, and GS staining). Calbindin (Calb, gray staining) was used as a Purkinje cell marker. Scale bars: 50 μm in Bergmann glia and 20 μm in VA and WM images. bv, blood vessel
FIGURE 9Molecular heterogeneity of astrocytes in the marmoset cerebellum. (A) Lower magnification images showing labeling for astrocytic proteins with respect to the molecular layer (ML), Purkinje cell layer (PCL), granule cell layer (GCL), and white matter (WM). Calbindin is used as a Purkinje cell marker. DAPI staining (blue) shows the nuclear staining of interneurons in the ML and granule cells in GCL. Scale bar: 100 μm. (B) Detailed images of ML and GCL stained with specific markers for Bergmann glia (BG) such as GluA1, Kirk4.1, and velate astrocytes (VA) such as AQP4. EAAT2 was expressed in both BGs and VAs with higher expression in VAs. Purkinje cell bodies are indicated with a white asterisk. Scale bar: 20 μm. bv, blood vessel
FIGURE 10Interactions of marmoset astrocytes with capillaries, neurons, and microglia. (A) Schema showing the gliovascular unit and blood vessel‐associated microglia. (B) GFAP and S100β labeling in astrocytic processes and endfeet surrounding a capillary in the marmoset cortex. Yellow circle shows high S100β expression and red circles highlight low S100β expression. Scale bar: 20 µm. (C) Cross‐sectional view of a capillary in the marmoset hippocampus displaying expression of AQP4 and GFAP at the astrocyte endfeet. Yellow arrowheads indicate GFAP expression at endfeet and white arrowheads indicate areas of co‐localization between GFAP and AQP4. Laminin (Lam) and DAPI labels show the basement membrane and nuclei of endothelial cells and pericytes (green arrowheads), respectively. Scale bars: 5 µm. (D) Cross‐sectional view of a capillary showing expression of Kir4.1 and GFAP at astrocyte endfeet and DAPI in endothelial cell and pericyte nuclei. Yellow arrowheads indicate GFAP expression, white arrowheads show areas of co‐localization between GFAP and Kir4.1, and green arrowheads highlight nuclei. Scale bars: 5 µm. (E–I) Co‐labeling of GFAP with neuronal markers including MAP2 (E, temporal cortex; G, hippocampus), Kv2.1 (F, temporal cortex; H hippocampus), and Calbindin (I, cerebellum). Higher magnification images are shown to the right of each panel (panels e′–i′). White arrowheads highlight the tight spatial neuronal‐astrocyte interaction. (J–L) Co‐labeling of GFAP with the microglial marker Iba1 in temporal cortex (J and K) and hippocampus (L). Images to the right of each panel (panels j′–l′) show higher magnifications. (J) Vessel‐associated microglia. Higher magnification images show microglia around the blood vessel (orange arrowheads) and microglia attached at the capillary (white arrowheads) (panels j′, j″). White arrowheads highlight the close spatial microglial–astrocyte interaction. Scale bars in panels E–L are 50 µm and e′–l′ are 20 µm. bv, blood vessel